Mitochondrial Calcium Dysregulation and Targeted Therapies in Heart Failure

Read full text Summarise with VIRAT
Authors: Mengting Liu, Yunpeng Jin
Cited by: 0
References: 109

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Heart failure (HF) is steadily increasing in prevalence and poses a major global health challenge, with substantial medical and economic burdens. HF represents the terminal stage of diverse cardiac disorders and is characterized by poor prognosis despite the availability of conventional pharmacological treatments, underscoring the urgent need for novel therapeutic approaches. Accumulating evidence highlights a strong association between HF and mitochondrial dysfunction, of which dysregulated mitochondrial calcium (mCa2+) homeostasis plays a pivotal role in disease pathogenesis. Ca2+ serves as an essential signaling messenger that regulates energy metabolism and also governs cell survival and myocardial contractility. Thus, this review introduces the mechanisms of mCa2+ uptake and efflux and the association of these processes with HF and emerging therapeutic strategies. We also discuss mCa2+ uniporter (MCU) inhibitors and Elamipretide, a mitochondria-targeted peptide. Collectively, this work provides novel insights and preclinical evidence supporting mitochondria-based interventions for HF.

Fields of Study & Subjects

Mitochondrial Function and Pathology Cardiac electrophysiology and arrhythmias Cardiac Ischemia and Reperfusion

Publication details

Journal / source
Reviews in Cardiovascular Medicine
Volume
27
Issue
3
Pages
46211–46211
Publication date
17 March 2026
Language
EN